Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TTK Healthcare Limited (TTKHLTCARE.NS)
Chennai, IN
TTK Healthcare Limited is a diversified enterprise operating across multiple sectors in India and globally. Its extensive activities encompass animal welfare, offering veterinary therapeutic solutions and feed supplements. The human pharmaceuticals division provides a range of herbal and allopathic formulations. Within consumer products, the company is responsible for marketing and distributing items such as Woodward's Gripewater, the EVA cosmetics line, and Good Home scrubbers and air fresheners. Its medical devices segment manufactures and supplies artificial heart valves, in addition to developing orthopedic implants and surgical instruments. Furthermore, TTK Healthcare produces and markets protective devices, including male contraceptives. The food segment specializes in manufacturing and selling processed food items like potato and cereal-based pellets. Notably, the company also engages in map and atlas printing and publishing through its 'Others' segment. Founded in 1958 and headquartered in Chennai, India, TTK Healthcare Limited operates as a subsidiary of TT Krishnamachari & Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.92% | +1.82% | -0.46% | +3.55% | -16.02% | -11.00% | -24.17% | -26.99% | +38.12% | -0.03% | -6.68% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - General: +6.6%-1.8% Q1'26: +14.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%-19.6% Q1'26: +34.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%-3.7% Q1'26: -11.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+10.0% Q1'26: +13.8% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+41.4% ★ Q1'26: +17.6% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.93× ★ Q1'26: 0.19× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2012 actual |
Mar 2013 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
|---|---|---|---|---|---|---|
| Revenue |
3.54B
est: 3.59B (-1.6%)
|
3.82B
est: 3.88B (-1.7%)
|
5.15B
est: 5.31B (-3.0%)
|
5.30B
est: 5.64B (-5.9%)
|
5.76B
est: 6.74B (-14.6%)
|
6.26B
est: 8.19B (-23.5%)
|
| EBITDA |
284.66M
est: 367.68M (-22.6%)
|
268.85M
est: 302.77M (-11.2%)
|
460.62M
est: 413.66M (+11.4%)
|
442.08M
est: 565.27M (-21.8%)
|
501.19M
est: 528.56M (-5.2%)
|
573.07M
est: 841.85M (-31.9%)
|
| EBIT |
260.18M
est: 300.80M (-13.5%)
|
240.56M
est: 232.32M (+3.5%)
|
387.65M
est: 317.41M (+22.1%)
|
322.92M
est: 462.45M (-30.2%)
|
347.86M
est: 322.57M (+7.8%)
|
425.19M
est: 688.72M (-38.3%)
|
| Net Income |
156.29M
est: 295.89M (-47.2%)
|
142.03M
est: 168.89M (-15.9%)
|
226.65M
est: 230.75M (-1.8%)
|
193.34M
est: 444.31M (-56.5%)
|
181.65M
est: 227.55M (-20.2%)
|
243.74M
est: 633.05M (-61.5%)
|
| SGA |
901.52M
est: 902.16M (-0.1%)
|
721.27M
est: 1.52B (-52.7%)
|
1.04B
est: 2.08B (-50.0%)
|
950.73M
est: 1.39B (-31.5%)
|
1.08B
est: 2.82B (-61.9%)
|
1.05B
est: 2.07B (-49.2%)
|
| EPS |
20.13
est: 20.94 (-3.9%)
|
18.29
est: 22.27 (-17.9%)
|
29.19
est: 29.88 (-2.3%)
|
24.13
est: 31.60 (-23.6%)
|
12.86
est: 37.16 (-65.4%)
|
17.25
est: 44.58 (-61.3%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 2/5 | 4/5 |
| 2026-06-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| T. T. Raghunathan | Executive Chairman | 49M | male |
| S. Kalyanaraman | Chief Executive Officer, MD & Director | 31M | male |
| V. K. Durga Prasad | President of Finance & Chief Financial Officer | 14M | male |
| Gowry A. Jaishankar | Deputy GM of Legal, Company Secretary & Compliance Officer | 2M | female |
| V. Senthil Kumar | Senior Vice President of Sales & Marketing - AWD | — | — |
| Brijj Balaji Singh | President of Operations (PDD) | — | male |
| Yogesh Yadav | President of CPD | — | male |
| K. Sunil | President of Heart Valve Division | — | male |
| S. Ranganath Rao | President of Foods Division | — | male |
| V. K. Srinivasan | Senior Vice President of Finance | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TTKHLTCARE.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
